Alembic Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged developing formulations and active pharmaceutical ingredients (API). The Company focuses on anti-infective, analgesic and, cough and cold therapies.
It also focuses on therapies, such as cardiology, diabetes, gynecology, gastrointestinal, orthopedic, dermatology and...
Alembic Pharmaceuticals Ltd - 10.12.2021
The stock is trading @ 810 levels
There is a strong resistance @ 825 levels
prices are above ema
stochastic overbought in weekly chart
there is a DOJI in weekly chart
Let the prices go above 827
watch out for the price action
Alembic Pharmaceuticals Ltd - 06.12.2021
The stock is trading @ 805.50 with a day's high of 825
The stock is trading under a channel range
Prices are above EMA
Let the prices go above 817
Watch out for the price action
Note:
1. Views are personal and for educational purposes only. Recheck and take the trade as per your RR.
2. Always remember SL is your lifeline, not the big target...
3. Follow us for more patterns and like, share so that we feel it is helpful to many and share more patterns...
3. Views given here is not a tip rather it is for educational purpose... Aftermarket...
The stock is now reversing after a good fall and it has made an inverse head and shoulder pattern on reversal. Can be bought for 1st,2nd and 3rd target of 860, 930 and 1000. CMP-790 and SL will be 750 on a closing basis. A 1:5 Risk Reward ratio. HIT the like button if you liked my analysis and do FOLLOW for more ideas.
Alembic Pharma gets EIR from USFDA for Karakhadi facility
The US regulator has also indicated that a compliance verification would be performed during re-inspection of the said facility in the next review cycle, it added.
This is in an uptrend for a while, recently it had formed a H&S pattern and now it had retested and rejected from it. I expect this scrip to fall further, it doesn't look like a major trend reversal but a correction which may continue for months. Swing traders may short it in futures are buy a PE to benefit from it. As it is in an overall uptrend, we should have...
